HALO

CinCor Pharma Raises $143 Million in Series B Financing

Retrieved on: 
Tuesday, October 12, 2021
History, Investment, Risk, Death, Adult, American Heart Association, Chronic kidney disease, Cardiology, GLOBE, Hypertension, Degenerative disease, Population, American College of Cardiology, Aldosterone, Collection, Eli Lilly and Company, Hope, General Atlantic, Kidney disease, Primary aldosteronism, Blood pressure, Stroke, HALO, Â, Patient, Disease, American College, CKD, Sofinnova, Pharmaceutical industry

CINCINNATI, Oct. 12, 2021 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) today announced the completion of a $143 million Series B financing. The proceeds from this round will support the continued development of CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase product candidate in development for the treatment of hypertension, primary aldosteronism and chronic kidney disease. The new funding will enable completion of the ongoing brigHTN Phase 2 clinical trial in patients with resistant hypertension as well as the ongoing Phase 2 Spark trial in hypertensive individuals with primary aldosteronism; in addition, it will support initiation of two new trials, a Phase 2 clinical trial (HALO) in patients with uncontrolled hypertension and a study of CIN-107’s impact on blood pressure and kidney function in patients with chronic kidney disease (CKD).

Key Points: 
  • Funding will support continued development of CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase product candidate, for the treatment of hypertension, primary aldosteronism and chronic kidney disease
    CINCINNATI, Oct. 12, 2021 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (CinCor) today announced the completion of a $143 million Series B financing.
  • CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases.
  • CinCor has raised $193 million to date in two private financings.
  • Though often asymptomatic, hypertension significantly increases the risk of heart disease, stroke and kidney disease, amongst other diseases.

HALO Diagnostics Launches Subtle Medical's Suite of AI-powered Imaging Technologies for Better Patient Care

Retrieved on: 
Tuesday, October 5, 2021
PET, Partnership, Man, MRI, Deep learning, Solution, Workflow, OEM, Patient, Physician, MD, HALO, Death, Genomics, Acquisition, Woman, Patient safety, Technology, Algorithm, Safety, Time, Prostate, Medical imaging

HALO has implemented both SubtleMR and SubtlePET image enhancement software at multiple locations, leading to higher quality imaging and improved patient experience.

Key Points: 
  • HALO has implemented both SubtleMR and SubtlePET image enhancement software at multiple locations, leading to higher quality imaging and improved patient experience.
  • "This combination allows us to better tailor scans to patient needs and improve workflow efficiency, patient experience, and patient safety.
  • The addition of Subtle Medical's technology to HALO Diagnostics furthers our commitment to precision focused, personalized healthcare."
  • HALO Diagnostics (HALO Dx, Inc.) changes patient lives and outcomes through early detection of the leading causes of death with precision diagnostics.

Longevity Science Foundation Pursuing 120+ Year Human Lifespan Launches In Switzerland

Retrieved on: 
Thursday, September 30, 2021
Cardiology, Biotechnology, Health, Philanthropy, General Health, Pharmaceutical, Research, Genetics, Foundation, Fitness & Nutrition, Science, University of Washington Department of Global Health, Human Longevity, National university, Decision-making, National Institute for Basic Biology, Japan, Solution, Therapy, American Aging Association, Center, Patient, Association, AI, HALO, CEO, Disability, Death, University, National University of Singapore, Awareness, Science, Buck Institute for Research on Aging, Human, Research, Foundation, Acceleration, Buck, Age, Pharmaceutical industry, Cardiology, Biotechnology, Health, Philanthropy, General Health, Pharmaceutical, Research, Genetics, Foundation, Fitness & Nutrition, Science

A consortium of biotech founders, clinicians, and leading longevity research institutions announced today the launch of the Longevity Science Foundation.

Key Points: 
  • A consortium of biotech founders, clinicians, and leading longevity research institutions announced today the launch of the Longevity Science Foundation.
  • The Longevity Science Foundation will provide funding to promising longevity research institutions and groups around the world.
  • The Longevity Science Foundation enables the rapid acceleration of basic science of human longevity and its translation towards human trials and clinical practice.
  • The Longevity Science Foundation is a Swiss non-profit organisation advancing human longevity by funding research and development of medical technologies to extend the healthy human lifespan to more than 120 years.

Version1 announces VersionX, its all-women's professional VALORANT team

Retrieved on: 
Thursday, September 23, 2021
Diamond, Wilf, Call of Duty League, Efuse, LAN, Partnership, Rocket League Championship Series, Minnesota Vikings, Astra, Infinity, The Main Event, Karra River, Call, Multimedia, Sincerity, Milky Way, Main, VALORANT, HALO, Environment, Philippine Esports Organization, Program, Rocket League, Female, Woman, Sage, Housing, Growth, Valorant, Counter Logic Gaming, Reyna, Viperidae, Organization, Investment, Insurance, Activision, CS, LoveHateHero, Name, VCT, Video game, Sport, Amusement arcade, Fireworks

EAGAN, Minn., Sept. 23, 2021 /PRNewswire/ -- Today, Version1 announced its fourth professional esports team, VersionX.  VersionX is an all-women's professional VALORANT team competing in the North American circuit of Verizon VCT Game Changers as well as open pro VALORANT events at all levels.

Key Points: 
  • VersionXisan all-women's professional VALORANT team competing inthe North American circuit ofVerizon VCT Game Changers as well as open pro VALORANT events at all levels.
  • VersionX is an all-women's professional VALORANT team competing in Verizon VCT Game Changers.
  • Milkyway has been a professional competitor since 2016, starting in Counter-Strike: Global Offensive (CS:GO) and transitioning to VALORANT in 2020.
  • Our professional teams include Minnesota Rkkr in the Call of Duty League, Version1 in Rocket League and Version1 in VALORANT.

Braided Lives: Troublin de Water: Catoctin Furnace's Enslaved through Poetry, Song, & Narrative

Retrieved on: 
Tuesday, September 14, 2021
Narrative, University of Maryland Human–Computer Interaction Lab, Program, State of Maryland Meritorious Civilian Service Medal, HALO, Humanities, Catoctin Furnace, African Americans, Maryland Department of Commerce, Vaccination, Strange Fruit, National Endowment for the Humanities, Maryland Historical Trust, CFHS, Element, Maryland Department of Planning, Catoctin, Person, Human, COVID, Learning, Research, Entertainment, Iron ore

CATOCTIN FURNACE, Md., Sept. 14, 2021 /PRNewswire-PRWeb/ --With generous support from Maryland Humanities, the Catoctin Furnace Historical Society is pleased to present Braided Lives: Troublin de Water: Catoctin Furnace's Enslaved through Poetry, Song, & Narrative.

Key Points: 
  • CATOCTIN FURNACE, Md., Sept. 14, 2021 /PRNewswire-PRWeb/ --With generous support from Maryland Humanities, the Catoctin Furnace Historical Society is pleased to present Braided Lives: Troublin de Water: Catoctin Furnace's Enslaved through Poetry, Song, & Narrative.
  • Braided Lives is an original, historically based multi-part presentation of video and live program crafted by Halo Quartet, Elayne Bond Hyman, and CFHS.
  • The village of Catoctin Furnace is a fraught landscape through which the enslaved persons of Catoctin Furnace were born, lived, worked, died, and were buried.
  • Theresa L. Donnelly, The Catoctin Furnace Historical Society, Inc., (443) 629-8661, [email protected]
    SOURCE The Catoctin Furnace Historical Society, Inc.

Late-Breaking Data at the International Headache Society & European Headache Federation Joint Congress 2021 Showed AJOVY® (fremanezumab-vfrm) Injection Reduced More Monthly Migraine Days in a Network Meta-Analysis Study with Atogepant and Rimegepant

Retrieved on: 
Wednesday, September 8, 2021
Science, Biotechnology, Research, Pharmaceutical, Medical Supplies, General Health, Health, Clinical Trials

For 12 weeks of double-blind treatment in FOCUS, 838 eligible patients were randomized one-to-one-to-one to quarterly fremanezumab, monthly fremanezumab or matched placebo.

Key Points: 
  • For 12 weeks of double-blind treatment in FOCUS, 838 eligible patients were randomized one-to-one-to-one to quarterly fremanezumab, monthly fremanezumab or matched placebo.
  • Change from baseline in monthly average maximum number of consecutive MFD was evaluated.
  • At baseline, mean numbers of maximum consecutive MFD were comparable across treatment groups (quarterly fremanezumab, 5.1 days [2.84]; monthly fremanezumab, 5.1 days [3.11]; placebo, 4.8 days [3.03]).
  • In all three studies, patients with CM or EM were randomized one-to-one-to-one to quarterly fremanezumab, monthly fremanezumab or matched placebo.

Get Immediate Health Status on Your Building and Impact on the Community With the New HALO Smart Sensor Release v2.5

Retrieved on: 
Wednesday, September 8, 2021

The HALO Smart Sensor, the worldwide leader for vape and vape with THC detection, is now helping facilities monitor their indoor health and air quality.

Key Points: 
  • The HALO Smart Sensor, the worldwide leader for vape and vape with THC detection, is now helping facilities monitor their indoor health and air quality.
  • As part of the newest v2.5 software release, HALO provides both a real-time air quality and Health Index and sends alerts when either index falls into danger zones.
  • In a recent survey, 73% of building occupants don't believe their building air is safe.
  • Capture real-time comprehensive building safety and health awareness with the all-in-one HALO Smart Sensor 2.5and the HALO Cloud Health Index.

Featuring the Largest Brands in Consumer Electronics and Healthcare, the 2021 Blue Light Summit Highlights Screen Time Solutions

Retrieved on: 
Thursday, September 2, 2021
People, Learning, UnitedHealth Group, AMD, Awareness, Blue Light, Technology, COVID-19, Life, Dell Technologies, Government, LG Display, OLED TV, UNH, United States Senate Committee on Commerce, Science, and Transportation, Screen time, Solution, Zagg, OLED, BOE Technology, Electronics, United Nations Global Compact, Company, HP, Safety, Industry, IVO, BenQ, CEO, TCL, HALO, Mobile, NYSE, Nightclub, Television, Mobile phone, Online shopping

Blue Light Summit 2021 will be held Sept. 28 (US/ Europe) and Sept. 29 (Asia-Pacific).

Key Points: 
  • Blue Light Summit 2021 will be held Sept. 28 (US/ Europe) and Sept. 29 (Asia-Pacific).
  • Blue Light Summit 2021 features many of the largest brands in consumer electronics, including BOE Technology Group, the world's largest display manufacturer, LG Display, the largest manufacturer of OLED TV displays, along with Dell Technologies, Lenovo, HP, Acer, TCL CSOT, IVO and BenQ.
  • The full line-up of speakers and presenters at the Blue Light Summit 2021 will be released in early September.
  • Eyesafe provides industry-leading solutions to reduce high-energy blue light, helping to re-design the consumer electronics industry toward better human health.

Showcasing Teva’s Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be presented, Including One Late-Breaker, on AJOVY® (fremanezumab-vfrm) Injection at the International Headache Society and European Headache...

Retrieved on: 
Monday, August 30, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Hypersensitivity, Congress, Research, Travel, CM, Neutralizing antibody, FOCUS, Solution, Teva, Angioedema, Anxiety, Country, University, Health care, Migraine, Forward-looking statement, Investment, Meta-analysis, NMA, Itch, Rimegepant, MFD, Anaphylaxis, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., TASE, MD, Scientific community, HALO, Medication overuse headache, IV, CEST, Vomiting, Abstract (summary), Perception, Contraindication, Failure, Reductions, Healthcare disparity in Massachusetts, International Headache Society, Private Securities Litigation Reform Act, Excipient, TEVA, Drug, Science, CGRP, Hives, NYSE, Compliance, Caregiver, Rash, Hypertension, Annual report, COVID-19, Headache, Pharmaceutical industry, Generic drug, Security printing, Aroma compound, Health insurance, Vaccine

Migraine affects over a billion people worldwide1, and its impact is felt by patients, caregivers, and society as a whole all around the world.

Key Points: 
  • Migraine affects over a billion people worldwide1, and its impact is felt by patients, caregivers, and society as a whole all around the world.
  • Migraine does not discriminate, and well discuss disparities in headache medicine across diverse populations during our Meet the Expert session.
  • Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials.
  • Adverse Reactions: The most common adverse reactions in clinical trials (5% and greater than placebo) were injection site reactions.

HALO LIFE's Breakthrough Makes Its Fashion Debut

Retrieved on: 
Saturday, August 28, 2021
Attitude, HALO, Instagram, Life, Research, DNA, LIFE, Sale, Light, Retail, Toy

Fashion remix Pan-Consumer Filed, lead you to the future lifestyle

Key Points: 
  • Shanghai, China--(Newsfile Corp. - August 28, 2021) - HALO LIFE has launched their first generation of the "LIFECODEX," a fashion product with a brand-new concept.
  • "Evolution," according to HALO LIFE, is a way to connect to the future.
  • HALO LIFE and TCI Bio teamed to research and design four functional foods that can be inserted within the tube of LIFECODEX.
  • The finished product is a spherical form with a lovely, eye-catching halo that allows you to explore the "universe" in the tube.